Investors of Regencell Bioscience Holdings Limited Can Join Class Action for Financial Recovery

Recovering Losses from Regencell Bioscience Holdings Limited

In light of the recent developments surrounding Regencell Bioscience Holdings Limited (NASDAQ: RGC), investors who faced financial setbacks are being offered a chance to join a class action lawsuit aimed at recovering their losses. This action is spearheaded by SueWallSt and is open to those who held shares during the period ranging from October 28, 2024, to October 31, 2025.

Background of Regencell's Market Valuation

Regencell gained notoriety for achieving a staggering market valuation of approximately $14 billion, despite having a mere twelve employees and no recorded revenue. Such a lofty valuation raises eyebrows, especially since the company reportedly spends around $1 million each year on research and development. Insights from the Wall Street Journal indicate that only a handful of companies within the Nasdaq Biotechnology Index surpassed Regencell's market valuation, despite the prevailing circumstances.

One of the key triggers for this extensive valuation appears to be trading activities detached from traditional business metrics. The lawsuit alleges that Regencell and its affiliates were aware of this 'manipulative' trading and failed to disclose it to their investors, resulting in inflated stock prices.

The Dramatic Price Surge and Subsequent Downfall

Analyzing Regencell's stock performance reveals an extraordinary fluctuation in its prices during the mentioned class period. At the outset of this period, shares were trading below $0.30. This alarming figure took an unexpected turn as Regencell's shares surged dramatically to a high of $78.00 on June 17, 2025—a staggering increase of 48,650%. No substantial news from the company validated this surge.

However, the euphoria was short-lived. Within a week of reaching its peak, shares plummeted to just over $20.00 before a further 18.56% drop on November 3, 2025, post the revelation of a U.S. Department of Justice (DOJ) subpoena regarding potential manipulation in trading activities connected to Regencell's ordinary shares.

Implications of the DOJ Investigation

The DOJ's actions have sparked scrutiny over Regencell's operations and trading activities. The company's annual report, released on October 31, 2025, confirmed receipt of a subpoena that requested documents related to its financial practices and called attention to the possibility of regulatory fines or penalties. This revelation contradicted previous statements from the company regarding its risks and market stability, painting a concerning portrait of Regencell's health and governance.

Joining the Class Action Lawsuit

For investors who purchased Regencell shares during the outlined period and suffered losses, there is an opportunity to participate in this class action lawsuit. Eligibility can extend to those who have already sold their shares but purchased them during the class period. Potential class members do not need to appear in court or provide testimony; they simply need to fill out a claim form to secure their potential recovery. SueWallSt operates on a contingency basis, meaning no upfront costs or fees will be required from participants.

Potential class members must take action swiftly, as the deadline to be considered as a lead plaintiff is set for June 23, 2026. Interested shareholders should gather their trading records, including purchase dates, quantities, and prices, and reach out to SueWallSt for a complimentary evaluation of their situation.

Conclusion

As Regencell’s tumultuous journey in the biotech sector unfolds, affected shareholders are encouraged to explore their legal options amidst this shrouded controversy. The outcome of the class action could hold significant implications for the future of investor security and corporate accountability. Whether you still hold your shares or sold them prior to the decline, your rights as a shareholder could enable you to seek recovery. For more information, reach out to Joseph E. Levi, Esq. via phone at (888) SueWallSt.